Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on March 22, 2007:
- Previous Holdings: 16,411,831 Ordinary Share ADRs
- New Holdings: 16,367,902 Ordinary Share ADRs
- Net Change: Decrease of 43,929 ADRs
- Average Price: $54.72
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J P Garnier and Dr. M M Slaoui are potentially interested in the shares held in the fund in the same manner as other beneficiaries.
Key Facts for Investor Verification
- The reduction in ADR holdings was driven by a fund movement within the US Retirement Savings Plan, not necessarily a direct sale by the directors.
- Directors Dr. J P Garnier and Dr. M M Slaoui hold indirect interests in the fund shares.
- The transaction was notified under Disclosure Rule 3.1.4R(1)(b).
- No financial performance data is included in this specific filing.